Tomer Meirson

Jul 11, 2023 | nature.com | Tomer Meirson

A recent report from the ATLAS trial comparing different maintenance strategies following haematopoeitic stem cell transplantation for multiple myeloma provides an opportunity to explore various themes of critical appraisal, including end points, the equipoise of trial design, and the part censoring can play in the validity of results. Refers to Dytfeld, D. et al.

Jun 29, 2023 | onlinelibrary.wiley.com | Tomer Meirson |Kelly Koehn |Aaron Goodman |Stijn Hentzen

Abstract Objectives Patients with multiple myeloma (MM) enrolled in randomized control trials (RCTs) discontinue treatment for various reasons; however, no prior study has analyzed reasons for discontinuation. We performed a systematic review of MM RCTs to investigate reasons for treatment discontinuation, imbalances between trial cohorts, and reporting practices. Methods A comprehensive search for RCTs in MM from 2015 to 2021 identified 45 studies meeting inclusion criteria.